Every AXLRx Gaucher Disease report, across 6 report types. Each is scoped to your asset and verified to a live source.
Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot.
Gaucher type 1 epidemiology, the Ashkenazi Jewish founder burden, GBA1 genotype–phenotype, and the 20-fold Parkinson's risk.
IV enzyme replacement buy-and-bill under Part B vs oral SRT under Part D, the CYP2D6 PA gate, and generic miglustat.
Three IV enzyme replacement brands run ~$300,000/year with no generic rival, so preferred-ERT designation is the real pricing lever. Eliglustat's CYP2D6 gate and generic miglustat's trial-first rule complete the picture.
The MedlinePlus-sourced count of 6,000 US Type 1 Gaucher patients sizes a market near $1.8 billion at ERT pricing, and the same population sits inside a genetic sub-segment where Ashkenazi carrier frequency runs 1 in 12-15 against a general-population disease frequency of just 0.70-1.75 per 100,000.
Five approved Type 1 Gaucher therapies treat the body, not the brain, and a genotype gate locks a meaningful share of the highest-prevalence population out of the only oral option. A Phase 3 gene therapy trial is now racing to close that gap.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, Pricing Strategy Model, Market Sizing Model, and Launch Readiness for Gaucher Disease. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Gaucher Disease coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Gaucher Disease reports were updated July 2026.